Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc. is a clinical-stage cell therapy company dedicated to developing next-generation T-cell therapies for cancer. The company's core mission is to advance effective cell therapies that can achieve lasting remissions for patients with both solid tumors and hematologic malignancies. Headquartered in South San Francisco, California, Lyell Immunopharma focuses on reprogramming T cells to overcome biological barriers such as T-cell exhaustion and enhance their cancer-killing capabilities.

Lyell's pipeline primarily consists of advanced Chimeric Antigen Receptor (CAR) T-cell product candidates. Key candidates include rondecabtagene autoleucel (ronde-cel, also known as LYL314 or IMPT-314), a dual-targeting CD19/CD20 CAR T-cell therapy in pivotal Phase 1/2 and Phase 3 trials for relapsed and/or refractory large B-cell lymphoma. Another significant product candidate is LYL273, a GCC-targeted CAR T-cell therapy in Phase 1 development for refractory metastatic colorectal cancer. The company also has LYL119, a next-generation ROR1-targeted CAR T-cell product candidate entering Phase 1 clinical development for platinum-resistant ovarian cancer or relapsed/refractory endometrial cancer. These therapies are enhanced with proprietary anti-exhaustion technologies and manufacturing protocols designed to improve T-cell function.

In recent notable developments, Lyell Immunopharma acquired ImmPACT Bio in October 2024, gaining exclusive rights to IMPT-314 and strategically focusing its pipeline on CAR T-cell programs, leading to the discontinuation of other programs. The company initiated patient dosing in the Phase 3 PiNACLE-H2H trial for aggressive large B-cell lymphoma in February 2026. Financially, Lyell closed an additional $50 million tranche of an equity private placement in March 2026, bringing total proceeds to approximately $100 million, which is expected to fund operations into Q2 2027. Lynn Seely, MD, serves as the President and Chief Executive Officer, appointed in December 2022. Lyell is positioned as a late-stage clinical biotechnology company, with analysts initiating coverage with positive ratings based on its pipeline potential.